AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Pompe Disease

AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Pompe Disease

Cambridge, MA, September 20, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the expansion of its pipeline to Pompe disease. This pre-clinical program becomes AVROBIO’s third gene therapy for Lysosomal Storage Disorders (LSDs), following a Phase 1 Fabry program and a pre-Phase 1/2 Gaucher program.